GSK uses "delay fees" to restrict competition and fined how old-brand pharmaceutical companies do it under the patent cliff

The plummeting rate of return on investment may be one of the main reasons why the original research drug companies choose to purchase small, streamlined, and potential product pipelines at a high price when their patents expire
.
By acquiring innovative drug companies to obtain valuable products, it can effectively avoid the losses caused by the failure of self-research of innovative drugs by enterprises, and at the same time, it can greatly shorten the investment cycle of new drugs
.
In recent years, such acquisitions abound
.

In recent years, new targets and new treatment methods have continued to emerge.
However, in the face of the current situation where the rate of return on independent research and development is not as good as that of small pharmaceutical companies, established pharmaceutical companies are also inclined to M&A, or similarly, obtaining new projects by way of license in.

.
However, with the prosperity of this trend, how will the independent R&D strength of the companies that craze money in this mode be maintained?